Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Mar 18;52(2):191–195. doi: 10.1007/s11055-022-01222-6

Postcovid-19 Asthenic Syndrome

I A Zolotovskaia 1,✉, P R Shatskaia 1, I L Davydkin 1, O A Shavlovskaya 2
PMCID: PMC8930482  PMID: 35317270

Abstract

Objective. To study the characteristics of asthenic syndrome and the potential for treating it in the postcovid period. Materials and methods. A continuous sampling method was used to select 129 patients (mean age 49.8 ± 8.9 years) after COVID-19. Study patients were selected at the clinical out-patient and polyclinic facilities in Samara in the period July–August, 2020. All patients signed informed consent. The envelope method was used to randomize patients into two groups: the study group (n = 64) received ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) three times daily for four weeks; medications in the reference group (n = 65) did not include any substances of the pharmacological antihypoxant/antioxidant/nootrope groups. Three visits (V) were made: the first (V1) was before inclusion in the study; the second (V2) was at 14 days; the third (V3) was on day 28 from treatment initiation. The dynamics of overall status (weakness, fatigue, concentration of attention, vertigo, headache, sleep impairment) were evaluated on a visual analog scale (VAS); the subjective perception of the severity of asthenia (tiredness, physical and mental fatigue, decreased motivation and activity) was evaluated using the Multidimensional Fatigue Inventory, MFI-20); cognitive functions were assessed using the Mini Mental State Examination (MMSA); and autonomic tone was assessed using the Kérdö index. Results. At the end of the study (V3), statistically significant changes in measures (VAS, MFI-20) were seen only in patients of the study group; the Kérdö Index showed no statistically significant differences. Analysis of MMSE data revealed a decline in cognitive functions in both groups, which may be linked with pseudocognitive deficit due to asthenia. Conclusions. Our studies yielded evidence of a high incidence of asthenic syndrome after COVID-19. Neurox decreased the severity and extent of the symptoms of asthenia.

Keywords: COVID-19, postcovid period, asthenia, asthenic syndrome, Neurox

Footnotes

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 4, Iss. 1, pp. 25–30, April, 2021.

References

  • 1.World Health Organization, Coronavirus Disease 2019 (COVID-19): Situation Report-55, WHO, Geneva (2020).
  • 2.Hozhabri H, Sparascio FS, Sohrabi H, et al. The global emergency of novel coronavirus (SARS-CoV-2): An update of the current status and forecasting. Int. J. Environ. Res. Public Health. 2010;17(16):5648. doi: 10.3390/ijerph17165648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 2020;109:102434. doi: 10.1016/j.jaut.2020.102434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J. Clin. Cases. 2020;8(17):3621–3644. doi: 10.12998/wjcc.v8.i17.3621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Li C, Wang LL. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. Virus Res. 2020;286:198073. doi: 10.1016/j.virusres.2020.198073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zheng L, Zhang L, Huang J, et al. Potential treatment methods targeting 2019-nCoV infection. Eur. J. Med. Chem. 2020;205:112687. doi: 10.1016/j.ejmech.2020.112687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rizk JG, Kalantar-Zadeh K, Mehra MR, et al. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020;80(13):1267–1292. doi: 10.1007/s40265-020-01367-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Abbot NC. Chronic fatigue syndrome. Lancet. 2006;67(9522):1574. doi: 10.1016/S0140-6736(06)68688-1. [DOI] [PubMed] [Google Scholar]
  • 9.Kotova OV, Akarachkova ES. Asthenic syndrome in the practice of a neurologist and a family doctor practice. Ross. Med. Zh. 2016;13:824–829. [Google Scholar]
  • 10.G. M. Dyukova, “Asthenic syndrome: problems of diagnosis and therapy,” Eff. Nevrol. Psikhiatr., No. 1, 16–22 (2012).
  • 11.Poverennova IE, Zolotovskaia IA, Bezgina EV. Diagnosis and treatment of asthenic syndrome in elderly people with acute respiratory viral infections. Zh. Nevrol. Psikhiatr. 2014;114(9):73–76. [PubMed] [Google Scholar]
  • 12.Shavlovskaya OA. Therapy of asthenic conditions in patients after stroke. Farmateka. 2013;19:56–61. [Google Scholar]
  • 13.A. N. Zinchuk, E. A. Zubach, A. Ya. Orfin, and O. Yu. Plevachuk, “Asthenic syndrome and its correction in patients with infectious pathology,” Semeinaya Med., No. 4, (84), 41–46 (2019).
  • 14.Maslennikova NA, Tikhonova EP, Mikhailova LA. Clinical aspects of hepatic echinococcosis. Sovrem. Prob. Nauki Obraz. 2018;5:22. [Google Scholar]
  • 15.Vorob’eva YD, Dyukova GM. Asthenic syndrome in the context of the COVID-19 pandemic. Meditsinsk. Alfavit. 2020;33:26–34. [Google Scholar]
  • 16.Zhestikova MG, Gerasimenko MY, Kan SL, et al. Management of COVID-19 patients with asthenic syndrome. Vrach. 2020;31:29–32. doi: 10.29296/25877305-2020-12-06. [DOI] [Google Scholar]
  • 17.Pennisi M, Lanza G, Falzone L, et al. SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms. Int. J. Mol. Sci. 2020;21(15):5475. doi: 10.3390/ijms21155475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Brown E, Gray R, Monaco SL, et al. The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research. Schizophr. Res. 2020;222:79–87. doi: 10.1016/j.schres.2020.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Trejo-Gabriel-Galán JM. Stroke as a complication and prognostic factor of COVID-19. Neurología. 2020;35(5):318–322. doi: 10.1016/j.nrl.2020.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front. Cell. Neurosci. 2018;12:386. doi: 10.3389/fncel.2018.00386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.E. M. Smets, B. J. Garssen, B. Bonke, and J. C. DeHaes, “The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue,” J. Psychosom. Res., 39, 315–325 (1995), https://doi.org/10.1016/0022-3999(94)00125-O. [DOI] [PubMed]
  • 23.I. Kérdö, ”Ein aus Daten der Blutzirkulation kalkulierter Index zur Beurteilung der vegetativen Tonuslage, Acta Neurovegetativa, 29, No. 2, 250–268 (1966). [DOI] [PubMed]
  • 24.M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental state: A practical method for grading the cognitive state of patients for the clinician,” J. Psychiatr. Res., 12, No. 3, 189–198 [DOI] [PubMed]
  • 25.Preobrazhenskaya IS. Mild and moderate cognitive disorders – clinical manifestations, etiology, pathogenesis, and the potential of nootropic therapy. Farmateka. 2013;4–13:14–18. [Google Scholar]
  • 26.A. Tsatsakis, D. Calina, L. Falzone, et al., “SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19,” J. Food Chem. Toxicol., 146, 111769 (2020), publ. online Sept. 30, 2020, https://doi.org/10.1016/j.fct.2020.111769. [DOI] [PMC free article] [PubMed]

Articles from Neuroscience and Behavioral Physiology are provided here courtesy of Nature Publishing Group

RESOURCES